CA72-4 Detection Service

Creative Biolabs is a leading service provider that focuses on tumor-associated glycan detection. Based on our advanced platforms and extensive experience, now we provide the novel CA72-4 detection service for the diagnostic of gastric cancer for our clients all over the world.

CA72-4 in Gastric cancer

Gastric cancer (GC) is one of the most common malignant tumors in the world, ranking fifth in global incidence and third in mortality. As a gastrointestinal tumor, GC presents high recurrence and metastasis rates. In recent decades, endoscopic examination and biopsy have been served as the primary tools for the diagnostic of GC, but always limited by the high cost and invasiveness. Therefore, it is of great significance to find sensitive biomarkers for the prognosis of patients with gastric cancer.

First described in the early 1980s, CA72-4 is a novel mucin-like high molecular weight glycoprotein antigen with a molecular weight of 220 to 400 kDa. It is almost not expressed in benign tumor tissues, body fluids, and normal tissues, but its high expression can be observed in multiple cancers, including gastrointestinal tumors, pancreatic cancer, endometrial cancer, ovarian cancer, as well as gastric cancer. Research data showed that nearly 40% of GC patients have a higher level of CA72-4 and increase with the progression of the disease. Combined with carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA19-9), it can be better used for the diagnosis and prognosis of GC patients.

Fig.1 ICTS construction process. Fig.1 Schematic diagram of immunochromatographic test strips (ICTS).¹

Techniques for CA72-4 Detection in Gastric Cancer

For CA72-4 detection, the total diagnostic accuracy rate of CA72-4 in detecting GC is 92.8%. What’s more, the sensitivity and specificity of CA72-4 to GC are significantly higher in patients with advanced GC than in early GC. Using a chemiluminescence kit is the easiest way to measure the level of serum CA72-4. A quantitative lateral flow immunoassay (LFIA) based on superparamagnetic nanoparticles (SPMNPs) is a rapid, sensitive, and quantitative approach for the detection of CA72-4 in human serum. The CA72-4 special monoclonal antibody is coupled onto SPMNPs to prepare the probes. After that, the intensity of the magnetic signal in the reaction zone can be quantified using a magnetization analyzer (MAR).

Creative Biolabs has been a long-term expert in the field of glycomics research. As a pioneer and the undisrupted global leader in tumor-associated glycan detection, we offer a variety of solutions to improve your productivity and streamline your research processes. If you are interested in our products or services, please do not hesitate to contact us for more detailed information.

Published data

CA72-4 is an important biomarker related to GC research. This study reports a quantitative, sensitive, and rapid method for the detection of CA72-4. The researchers coupled an anti-CA72-4 monoclonal antibody (mAb) with the fluorescent signal from quantum dots (QD) to provide a fluorescent signal for recognition. They then constructed immunochromatographic test strips (ICTS) using the labeled mAb and unlabeled mAb. Upon addition of the sample, both antibodies and CA72-4 formed a sandwich structure. The amount of CA72-4 detected correlated with the fluorescence signal. To validate the specificity and efficacy of the method, the researchers used the method to detect CA72-4 in 100 serum samples from GC and healthy individuals. The results showed that this method was simple to perform, yielded sensitive quantitative results, and had high specificity compared to the electrochemiluminescence assay from Roche. The method has great potential for clinical translation. This strategy is also applicable to the development of test strips for the detection of multiple markers. This study not only guides the development of clinical diagnostic reagents for GC but also helps to predict the effectiveness of tumor treatment methods.

Fig.2 Use of ICTS to detect CA72-4 in serum samples. Fig.2 Detection of CA72-4.¹

FAQs

Q1: What are the characteristics of CA72-4 detection methods?

A1: The main methods to detect CA72-4 are enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), and electrochemiluminescence immunoassay (ECLIA).

ECLIA is a highly efficient method for detecting serum tumor markers. It is characterized by simple operation, simplified optical devices, and controllability.
With high throughput, fast analysis speed, good selectivity, and high sensitivity, CLIA is optimized to detect various tumor markers.
ECLIA continues to develop and mature and has good application value in tumor marker detection due to its high sensitivity and fast response time.

Q2: What is the general testing procedure for CA72-4?

A2: We develop customized CA72-4 assays tailored to our client's specific research goals and sample types.

Sample processing: Various types of samples such as serum, plasma, tissue, etc., are processed by homogenization, centrifugation, etc., for subsequent CA72-4 testing.
CA72-4 detection: CA72-4 is detected using appropriate methods (ELISA, CLIA).
CA72-4 analysis: The concentration of CA72-4 in the sample is calculated and the results are analyzed.

Customer Review

Efficient CA72-4 Detection
"Creative Biolabs developed a detailed CA72-4 testing program after communicating with us. With their advanced technology, they helped us detect the CA72-4 content in our samples and provided us with a detailed analysis report, which helped us better analyze the effect of targeted cancer therapy. Their commitment to service quality was commendable."

Preferred Partner for Tumor-associated Glycan Analysis
"From the communication with Creative Biolabs and the delivery of the final results, it was clear that they had extensive experience in tumor-associated glycan detection. Their researchers used efficient means to analyze the CA72-4 levels in our samples. The communication between us throughout the project was also very efficient. There was no doubt that they are a preferred partner in this area."

Reference

Yan, Xinyu, et al. "CdSe/ZnS quantum dot-labeled lateral flow strips for rapid and quantitative detection of gastric cancer carbohydrate antigen 72-4." Nanoscale Research Letters 11 (2016): 1-8. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only.